This creates a dual metabolic lever: reduced energy intake (via GLP-1/GIP appetite suppression) combined with increased energy output (via glucagon-mediated thermogenesis)
Moreover, because discontinuation of GLP-1RAs often leads to weight regain, these medications must be regarded as a chronic therapy to sustain weight loss and prevent associated negative health outcomes
References (17) Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, et al
Hunger cues fade
If a treatment isnt the right fit for your specific concern, well say so and point you toward what will actually work
Effect of oxyntomodulin, glucagon, GLP-1, and combined glucagon +GLP-1 infusion on food intake, appetite, and resting energy expenditure